Status:
TERMINATED
Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)
Lead Sponsor:
Nordic Bioscience A/S
Collaborating Sponsors:
Novartis
Conditions:
Osteoarthritis
Eligibility:
All Genders
51-80 years
Phase:
PHASE3
Brief Summary
The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee
Eligibility Criteria
Inclusion
- Medical history and symptoms of knee osteoarthritis
Exclusion
- Any other disease or medication affecting the bone or cartilage.
- Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.
- Other protocol defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
1030 Patients enrolled
Trial Details
Trial ID
NCT00704847
Start Date
June 1 2008
End Date
June 1 2011
Last Update
April 24 2019
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Achieve Clinical Research, LLC
Tuscaloosa, Alabama, United States, 35406
2
Center for Healthy Aging
Sacramento, California, United States, 95817
3
Northwestern Center for Clinical Research
Chicago, Illinois, United States, 60611
4
Midwest Pharmaceutical Research
City of Saint Peters, Missouri, United States, 63376